Kantonsspital St.Gallen
login

Lilly RHCF SPIRIT

Mira Bartz Batliner, Silvia Forrer, Carina Hutz, Andrea Rubbert Roth & Thomas Neumann

abstract A 52-Week Multicenter, Randomized, Open-Label, Parallel-
Group Study Evaluating the Efficacy and Safety of
Ixekizumab versus Adalimumab in Patients with Psoriatic
Arthritis Who Are Biologic Disease-Modifying Anti-Rheumatic
Drug Naive
   
type of project clinical studies
status completed
start of project 2017
end of project 2021
study design Psoriasis, Arthritis, Biologika naïve, adalimumab, ixekizumab
responsible person Prof. Dr. Rubbert-Roth